# A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

> **NCT04569032** · PHASE2 · COMPLETED · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 82 (actual)

## Conditions studied

- Peripheral T-cell Lymphoma

## Interventions

- **DRUG:** brentuximab vedotin
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin
- **DRUG:** prednisone

## Key facts

- **NCT ID:** NCT04569032
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-12
- **Primary completion:** 2024-05-09
- **Final completion:** 2026-01-12
- **Target enrollment:** 82 (ACTUAL)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04569032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04569032, "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04569032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*